Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Reviews: Inspector General Weighs In, But Progress Depends On Congress

Executive Summary

A report by the HHS Office of Inspector General on FDA's review process for generic drugs illuminates the challenges the agency faces, but reaction to the report underscores the impression that complete resolution of the issue will require Congressional intervention

You may also be interested in...



Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority

FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia

Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority

FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia

180-Day Exclusivity Decision On Acarbose Illustrates Importance Of ANDA Quality

FDA's decision to deny Cobalt 180-day exclusivity for its ANDA of acarbose (Bayer's diabetes treatment Precose) illustrates the importance for generic firms of submitting high-quality applications

Related Content

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel